|
KMID : 0378019910340020113
|
|
New Medical Journal
1991 Volume.34 No. 2 p.113 ~ p.116
|
|
|
Clinical Efficacy of Roxithromycin in Community-acquired Lower Respiratory Tract Infections
|
|
|
|
|
Abstract
|
|
|
Roxithromycin(RU 28965, RM) is one of the newer semisynthetic macrolide which has antimicrobial activities similar to erythromycin. RM is claimed to have longer half life, to be non-nauseating and acid stable. Authors assessed clinical efficacy and safety of RM among patients with community-acquired lower respiratory tract infections.
Patients with acute suppurative bronchitis(n=7) and acute pneumonia(n=19), who were previously healthy and free of chronic respiratory diseases, were given RM 150mg, b.i.d. orally. In bronchitis group, all seven patients (100%) achieved clinical success. In pneumonia group, eighteen out of nineteen patients(95%) achieved clinical and radiological success. Two patients showed transient rise of serum transaminase levels and one developed mild epigastric discomfort.
From these results we concluded that RM is highly effective and safe antibiotics in the treatment of community-acquired lower respiratory tract infections.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|